The Phase 3 APPROACH topline data in Q4 2026 is the primary catalyst. Monitor for any interim updates or safety signals. The $166.4M cash position reduces near-term dilution risk. The new CEO's commercial experience may improve market perception.
Price Chart
Executive Summary
Helus Pharma reported Q4 fiscal 2026 (period ended March 31, 2026) EPS of -$1.17, beating consensus of -$1.38 by 15.5%. The clinical-stage biotech completed enrollment in its Phase 3 APPROACH study for HLP003 in MDD with topline data expected in Q4 2026, and reported positive Phase 2 data for HLP004 in GAD. The company also strengthened its balance sheet with a $50M underwritten offering in June 2026, ending the quarter with $166.4M in cash.
Key Financial Metrics
Key Facts
- Completed enrollment in Phase 3 APPROACH pivotal study for HLP003 in Major Depressive Disorder; topline data on track for Q4 2026
- EPS of -$1.17 beat consensus of -$1.38 by 15.5%
- Net loss widened to $47.8M from $24.6M in the prior-year quarter, driven by Phase 3 trial costs
- Cash balance of $166.4M as of June 30, 2026, following a $50M underwritten offering in June 2026
- Appointed Michael Halstead (former President of Intra-Cellular Therapies) as CEO
- Positive Phase 2 data for HLP004 in GAD, including statistically significant improvement and durable effects through six months
- Completed DDI study showing no meaningful PK interactions with CYP450 substrates, supporting adjunctive use in MDD
Financial Impact
EPS beat by 15.5% on a pre-revenue clinical-stage company — not financially material. Net loss increased 94% YoY to $47.8M, but cash position of $166.4M provides runway into late 2027.
Risk Factors
- Phase 3 topline data for HLP003 may miss efficacy or safety endpoints
- Net loss is increasing rapidly as trials advance, potentially requiring additional financing beyond current cash runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345256 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.57 (+4.55%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.57 (−2.63%) |
Oct 23, 2026 2d ago | 3 | $10.50 | awaiting T+20 | — | $10.57 (+0.67%) |
Oct 23, 2026 2d ago | 3 | $10.50 | awaiting T+20 | — | $10.57 (+0.67%) |
Oct 23, 2026 2d ago | 3 | $10.50 | awaiting T+20 | — | $10.57 (+0.67%) |
Oct 23, 2026 2d ago | 3 | $10.50 | awaiting T+20 | — | $10.57 (+0.67%) |
Oct 21, 2026 4d ago | 6-K | $10.50 | awaiting T+20 | — | $10.57 (+0.67%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.57 (−4.34%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.57 (−4.34%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.57 (−1.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers